{"content":"<li class=\"n-box-item date-title\" data-end=\"1560830399\" data-start=\"1560744000\" data-txt=\"Monday, December 23, 2019\">Monday, June 17, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3471939\" data-ts=\"1560809185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471939-turtle-beachplus-2_8-director-buys-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turtle Beach +2.8% as director buys more shares</a></h4><ul>   <li>Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) is making its second postmarket move in a row following a share purchase by director Ronald Doornink.</li>    <li>On Friday, Doornink <a href=\"https://seekingalpha.com/news/3471584-turtle-beach-plus-3_5-percent-director-buys-shares\" target=\"_blank\">disclosed a purchase</a> of 4,938 shares, and the stock moved up in the after-hours session.</li>    <li>Shares are <font color=\"green\">up 2.8%</font> after hours today following a <a href=\"https://seekingalpha.com/filing/4535329\" target=\"_blank\">new Form 4 from Doornink</a>, indicating a purchase of another 5,000 shares on Friday at an average  price of $10.47.</li>    <li>That adds to an indirect holding by the Doornink Revocable Living Trust, now beneficial owner of 383,886 shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471939\" data-linked=\"Turtle Beach +2.8% as director buys more shares\" data-tweet=\"$HEAR - Turtle Beach +2.8% as director buys more shares https://seekingalpha.com/news/3471939-turtle-beachplus-2_8-director-buys-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3471939-turtle-beachplus-2_8-director-buys-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471935\" data-ts=\"1560808503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHVN\" target=\"_blank\">BHVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471935-biohaven-pharmaminus-13_4-after-mixed-shelf-registration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biohaven Pharma -13.4% after mixed shelf registration</a></h4><ul>   <li>Biohaven Pharmaceutical Holding (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) is <font color=\"red\">13.4% lower</font> after hours on robust volume following a <a href=\"https://seekingalpha.com/filing/4535434\" target=\"_blank\">mixed shelf registration</a>.</li>    <li>With the filing, the company may from time to time offer common shares, preferred shares, depositary shares, debt securities, warrants, rights, purchase contracts and/or units.</li>    <li>Any proceeds are designated for general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471935\" data-linked=\"Biohaven Pharma -13.4% after mixed shelf registration\" data-tweet=\"$BHVN - Biohaven Pharma -13.4% after mixed shelf registration https://seekingalpha.com/news/3471935-biohaven-pharmaminus-13_4-after-mixed-shelf-registration?source=tweet\" data-url=\"https://seekingalpha.com/news/3471935-biohaven-pharmaminus-13_4-after-mixed-shelf-registration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471933\" data-ts=\"1560807449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471933-healthcare-dominate-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare dominate after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a> <font color=\"green\">+117.9%</font>. <a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a> <font color=\"green\">+14.0%</font>. <a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a> <font color=\"green\">+7.4%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color=\"green\">+4.9%</font>. <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color=\"green\">+2.7%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a> <font color=\"red\">-21.8%</font>. <a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color=\"red\">-15.4%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences, Inc.'>CALA</a> <font color=\"red\">-8.6%</font><a href='https://seekingalpha.com/symbol/ESV' title='Ensco Rowan plc'>ESV</a> <font color=\"red\">-1.9%</font>. <a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd.'>VEON</a> <font color=\"red\">-0.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471933\" data-linked=\"Healthcare dominate after hour movers\" data-tweet=\"$MGI $PHAS $NSPR - Healthcare dominate after hour movers https://seekingalpha.com/news/3471933-healthcare-dominate-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471933-healthcare-dominate-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471931\" data-ts=\"1560806771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STLD\" target=\"_blank\">STLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471931-steel-dynamics-sees-below-consensus-q2-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel Dynamics sees below-consensus Q2 earnings</a></h4><ul><li>Steel Dynamics (NASDAQ:<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a>) <font color=\"red\">-2.8%</font> after-hours as it <a href=\"https://seekingalpha.com/pr/17546848-steel-dynamics-provides-second-quarter-2019-earnings-guidance\" target=\"_blank\">guides Q2 EPS of $0.86-$0.90</a>, below Q1 and year-ago results as well as Wall Street expectations.</li><li>STLD's anticipated Q2 range is below Q1 earnings of $0.91/share and Q2  2018 EPS of $1.53, and the analyst consensus EPS estimate for the  quarter is $0.94.</li><li>STLD expects Q2 earnings from its steel operations to decline relative to Q1, primarily due to lower profitability from  its long product steel operations, as shipments and metal  spread declined in the quarter; while underlying domestic steel demand  remains intact, steel buying hesitancy and inventory destocking  has been caused by a weakening scrap price environment.</li><li>Q2 profitability in the company's metals recycling platform also is seen declining, based mostly on reduced ferrous metal spread as average pricing declined  through the quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471931\" data-linked=\"Steel Dynamics sees below-consensus Q2 earnings\" data-tweet=\"$STLD - Steel Dynamics sees below-consensus Q2 earnings https://seekingalpha.com/news/3471931-steel-dynamics-sees-below-consensus-q2-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3471931-steel-dynamics-sees-below-consensus-q2-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471928\" data-ts=\"1560806098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHAS\" target=\"_blank\">PHAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471928-phasebioplus-12-on-prelim-pb2452-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PhaseBio +12% on prelim PB2452 data</a></h4><ul><li>PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <a href=\"https://seekingalpha.com/pr/17546733-phasebio-announces-positive-preliminary-results-phase-2a-clinical-trial-pb2452-reversal\" target=\"_blank\">announces</a> preliminary data from its Phase 2a clinical trial of PB2452.</li><li>The trial includes  older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.</li><li>Statistically significant reversal of ticagrelor was achieved within 5 minutes of the PB2452 infusion initiation and sustained for over 20 hours. Platelet function was normalized by 15 minutes following initiation and remained normal for over 20 hours.</li><li>PHAS shares are <font color=\"green\">up 12%</font> after hours to $13.71.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471928\" data-linked=\"PhaseBio +12% on prelim PB2452 data\" data-tweet=\"$PHAS - PhaseBio +12% on prelim PB2452 data https://seekingalpha.com/news/3471928-phasebioplus-12-on-prelim-pb2452-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3471928-phasebioplus-12-on-prelim-pb2452-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471925\" data-ts=\"1560805785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471925-eiger-biopharmaplus-4_9-avexitide-designated-breakthrough-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eiger BioPharma +4.9% as avexitide designated Breakthrough Therapy</a></h4><ul>   <li>Eiger BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a>) is <font color=\"green\">up 4.9%</font> in relatively light postmarket trading after noting its avexitide treatment got <a href=\"https://seekingalpha.com/pr/17546777-eiger-announces-breakthrough-therapy-designation-granted-fda-avexitide-treatment-post\" target=\"_blank\">Breakthrough Therapy designation</a> from the FDA, putting it on a fast track.</li>    <li>That comes for the treatment of post-bariatric hypoglycemia, a condition occurring in post-bariatric surgical patients leading to dangerously plow postprandial blood glucose.</li>    <li>The company has seen promising results from a program that's dosed 54 patients across four Phase 2 studies, it says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471925\" data-linked=\"Eiger BioPharma +4.9% as avexitide designated Breakthrough Therapy\" data-tweet=\"$EIGR - Eiger BioPharma +4.9% as avexitide designated Breakthrough Therapy https://seekingalpha.com/news/3471925-eiger-biopharmaplus-4_9-avexitide-designated-breakthrough-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3471925-eiger-biopharmaplus-4_9-avexitide-designated-breakthrough-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471929\" data-ts=\"1560805544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471929-lannett-oks-cody-labs-restructuring-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lannett OKs Cody Labs restructuring plan</a></h4><ul><li>Lannett (NYSE:<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc.'>LCI</a>) <font color=\"green\">+3.7%</font> after-hours upon disclosure that it <a href=\"https://www.sec.gov/Archives/edgar/data/57725/000110465919035950/a19-11653_18k.htm\" target=\"_blank\">approved a restructuring plan</a> for Cody Laboratories, which will include reduction of all 70 remaining positions at the subsidiary.</li><li>LCI says it has been unable to sell the Cody API business as an ongoing operation and instead will ease all operations.</li><li>LCI estimates it will incur ~$5M of total costs to implement the Cody API restructuring plan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471929\" data-linked=\"Lannett OKs Cody Labs restructuring plan\" data-tweet=\"$LCI - Lannett OKs Cody Labs restructuring plan https://seekingalpha.com/news/3471929-lannett-oks-cody-labs-restructuring-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3471929-lannett-oks-cody-labs-restructuring-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471904\" data-ts=\"1560804112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471904-sorrento-therapeuticsminus-6_3-oaktree-files-for-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento Therapeutics -6.3% as Oaktree files for share offering</a></h4><ul>    <li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) is <font color=\"red\">6.3% lower</font> postmarket following a <a href=\"https://seekingalpha.com/filing/4535144\" target=\"_blank\">filing for a share offering</a> by shareholder Oaktree Capital Management.</li>    <li>The firm has registered 1.333M shares; it's currently beneficial owner of a 4.9% stake.</li>    <li>The filing doesn't mean Oaktree will necessarily offer or sell any of the shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471904\" data-linked=\"Sorrento Therapeutics -6.3% as Oaktree files for share offering\" data-tweet=\"$SRNE - Sorrento Therapeutics -6.3% as Oaktree files for share offering https://seekingalpha.com/news/3471904-sorrento-therapeuticsminus-6_3-oaktree-files-for-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3471904-sorrento-therapeuticsminus-6_3-oaktree-files-for-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471902\" data-ts=\"1560803781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGI\" target=\"_blank\">MGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471902-moneygramplus-53-after-partnering-ripple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoneyGram +53% after partnering with Ripple</a></h4><ul> <li>MoneyGram International (NASDAQ:<a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a>) skyrockets after announcing a strategic agreement with Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>).</li><li>MoneyGram says the two-year partnership supports the companies' shared goal of improving the settlement of cross-border payments by increasing efficiency and reducing cost through RippleNet.</li>                 <li>Ripple will become MoneyGram's key partner for cross-border settlement using digital assets. As part of this partnership, Ripple has made an initial investment of $30M in MoneyGram equity, made up of common stock and a warrant to purchase common stock. Ripple purchased the newly-issued common stock from MoneyGram at $4.10 per share.</li><li>MGI  <font color=\"green\">+52%</font> after hours to  $2.22.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/17546813-moneygram-announces-strategic-partnership-ripple\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3471902\" data-linked=\"MoneyGram +53% after partnering with Ripple\" data-tweet=\"$MGI $MGI $XRP-USD - MoneyGram +53% after partnering with Ripple https://seekingalpha.com/news/3471902-moneygramplus-53-after-partnering-ripple?source=tweet\" data-url=\"https://seekingalpha.com/news/3471902-moneygramplus-53-after-partnering-ripple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471891\" data-ts=\"1560803292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PINS\" target=\"_blank\">PINS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471891-pinterest-gains-wedbush-another-bull\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pinterest gains Wedbush as another bull</a></h4><ul><li>Wedbush starts Pinterest (NYSE:<a href='https://seekingalpha.com/symbol/PINS' title='Pinterest, Inc.'>PINS</a>) with an Outperform rating and a $33 PT (18% upside).</li><li>Last month, analyst <a href=\"https://seekingalpha.com/news/3464963-analysts-shrug-pinterest-print\" target=\"_blank\">shrugged off</a> Pinterest's first print, which came with a wider-than-expected loss and downside FY guidance. Analysts were confident in the PINS growth story, including the international sales ramp.</li><li>Pinterest shares are <font color=\"green\">up 0.8% </font>after the close to $28.06.</li><li>PINS has a Neutral average<a href=\"https://seekingalpha.com/symbol/PINS/ratings/author-ratings#filter=all\" target=\"_blank\"> SA Authors' rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471891\" data-linked=\"Pinterest gains Wedbush as another bull\" data-tweet=\"$PINS - Pinterest gains Wedbush as another bull https://seekingalpha.com/news/3471891-pinterest-gains-wedbush-another-bull?source=tweet\" data-url=\"https://seekingalpha.com/news/3471891-pinterest-gains-wedbush-another-bull\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471886\" data-ts=\"1560802667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMTI\" target=\"_blank\">RMTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471886-rockwell-medical-slides-23-on-new-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rockwell Medical slides 23% on new share offering</a></h4><ul>   <li>Rockwell Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a>) is <font color=\"red\">22.9% lower</font> postmarket after launching a <a href=\"https://seekingalpha.com/pr/17546731-rockwell-medical-announces-proposed-public-offering-common-stock\" target=\"_blank\">share offering</a>.</li>    <li>Book-runners are Piper Jaffray and Cantor Fitzgerald.</li>    <li>Underwriters will get a 30-day optino to buy up to an additional 15% of shares.</li>    <li>Proceeds will be used for the commercialization of Dialysate Triferic and I.V. Triferic, as well as research and development and general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471886\" data-linked=\"Rockwell Medical slides 23% on new share offering\" data-tweet=\"$RMTI - Rockwell Medical slides 23% on new share offering https://seekingalpha.com/news/3471886-rockwell-medical-slides-23-on-new-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3471886-rockwell-medical-slides-23-on-new-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471870\" data-ts=\"1560801424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471870-dish-network-launches-system-installation-brand-for-consumers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish Network launches system-installation brand for consumers</a></h4><ul>   <li>Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"green\">+3.8%</font>) has launched a new direct-to-consumer brand to help customers set up their now-smarter entertainment systems.</li>    <li>It's created <a href=\"https://seekingalpha.com/pr/17546160-dish-launches-ontech-smart-services-new-direct-consumer-smart-home-solutions-brand\" target=\"_blank\">OnTech Smart Services</a>, which offers end-to-end installation of products from Google Nest, Ring, Linksys, Wemo, Roku, Yale, Polk Audio and Klipsch Audio among others.</li>    <li>Customers will be able to buy products directly from the OnTech website and schedule deliver/installation as soon as the same day.</li>    <li>It's launching today in 11 major markets with plans to expand in the near future.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471870\" data-linked=\"Dish Network launches system-installation brand for consumers\" data-tweet=\"$DISH - Dish Network launches system-installation brand for consumers https://seekingalpha.com/news/3471870-dish-network-launches-system-installation-brand-for-consumers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471870-dish-network-launches-system-installation-brand-for-consumers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471868\" data-ts=\"1560801142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGN\" target=\"_blank\">ALGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471868-align-ends-straumann-distribution-deal-otr-global-out-cautious-on-invisalign\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Align ends Straumann distribution deal; OTR Global out cautious on Invisalign</a></h4><ul><li>Align Technology (<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a> <font color='red'>-5.5%</font>) tumbles, apparently in reaction to Friday's news that <a href=\"https://seekingalpha.com/pr/17544709-align-technology-straumann-group-terminate-discussions-concerning-possible-development\" target=\"_blank\">talks had ended</a> between the company and Straumann Group over a possible development and distribution agreement that was disclosed in March as part of a patent settlement agreement.</li><li>Also, researcher OTR Global reportedly issued <a href=\"https://www.streetinsider.com/Analyst+Comments/OTR+Global+Said+to+Make+Cautious+Comments+on+Align+Technology+%28ALGN%29/15617428.html\" target=\"_blank\">cautious commentary</a> on ALGN and sales of the company's Invisalign clear aligner system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471868\" data-linked=\"Align ends Straumann distribution deal; OTR Global out cautious on Invisalign\" data-tweet=\"$ALGN - Align ends Straumann distribution deal; OTR Global out cautious on Invisalign https://seekingalpha.com/news/3471868-align-ends-straumann-distribution-deal-otr-global-out-cautious-on-invisalign?source=tweet\" data-url=\"https://seekingalpha.com/news/3471868-align-ends-straumann-distribution-deal-otr-global-out-cautious-on-invisalign\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471867\" data-ts=\"1560800801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471867-j-jill-mounts-mini-comeback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J. Jill mounts mini comeback</a></h4><ul> <li>J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J.Jill, Inc.'>JILL</a>) is <font color=\"green\">up 9.36%</font> as shares make a minor dent in the 69% YTD drop that's been carved out.</li> <li>Investors are trying to evaluate the retailer after a rough Q2 that saw J. Jill management concede to having execution and design issues. \"We did not move fast enough with aggressive action to address the trends that persisted,\" noted CEO Linda Heasley on the firm's earnings call (<a href=\"https://seekingalpha.com/article/4267307-j-jill-inc-s-jill-ceo-linda-heasley-q1-2019-results-earnings-call-transcript\" target=\"_blank\">transcript</a>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471867\" data-linked=\"J. Jill mounts mini comeback\" data-tweet=\"$JILL - J. Jill mounts mini comeback https://seekingalpha.com/news/3471867-j-jill-mounts-mini-comeback?source=tweet\" data-url=\"https://seekingalpha.com/news/3471867-j-jill-mounts-mini-comeback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471861\" data-ts=\"1560799398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471861-soggy-day-for-meat-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soggy day for meat stocks</a></h4><ul> <li>Meat stocks are slumping amid concerns about the impact of the flooding in the U.S. Midwest.</li> <li>Sanderson Farms (<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='red'>-6.3%</font>), Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-3.3%</font>), Hormel (<a href='https://seekingalpha.com/symbol/HRL' title='Hormel Foods Corporation'>HRL</a> <font color='red'>-1.1%</font>) and Tyson Foods (<a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods, Inc.'>TSN</a> <font color='red'>-4%</font>) are all lower on the day with more rain added to the amount of flooded farmland and anticipated to increase corn and soybean costs for the producers.</li> <li>All four stocks have racked up double digit gains this year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471861\" data-linked=\"Soggy day for meat stocks\" data-tweet=\"$SAFM $PPC $HRL - Soggy day for meat stocks https://seekingalpha.com/news/3471861-soggy-day-for-meat-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3471861-soggy-day-for-meat-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471859\" data-ts=\"1560798491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLDM\" target=\"_blank\">FLDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471859-fluidigm-introduces-seven-new-metal-markers-for-mass-cytometry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fluidigm introduces seven new metal markers for mass cytometry</a></h4><ul><li>Fluidigm (<a href='https://seekingalpha.com/symbol/FLDM' title='Fluidigm Corporation'>FLDM</a> <font color='green'>+2%</font>) says it will <a href=\"https://seekingalpha.com/pr/17546067-fluidigm-scales-highly-multiplexed-cell-analysis-introduction-seven-new-metal-markers\" target=\"_blank\">introduce seven new cadmium metal labeling kits</a> for mass cytometry in Q3, making its system capable of supporting as many as 50 cell surface and intracellular parameters at a time.</li><li>Representing the first of a series of new metal isotopes in development, FLDM says the new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development.</li><li>Piper Jaffray analyst William Quirk reiterates his Overweight rating and $16 price target on the shares, saying the announcement solidifies FLDM's competitive position and places the company in a position to beat Wall Street expectations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471859\" data-linked=\"Fluidigm introduces seven new metal markers for mass cytometry\" data-tweet=\"$FLDM - Fluidigm introduces seven new metal markers for mass cytometry https://seekingalpha.com/news/3471859-fluidigm-introduces-seven-new-metal-markers-for-mass-cytometry?source=tweet\" data-url=\"https://seekingalpha.com/news/3471859-fluidigm-introduces-seven-new-metal-markers-for-mass-cytometry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471856\" data-ts=\"1560797904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471856-fire-knocks-out-pollution-controls-u-s-steels-clariton-coke-plant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fire knocks out pollution controls at U.S. Steel&#39;s Clariton coke plant</a></h4><ul><li>U.S. Steel's (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+1.7%</font>) Clairton coke facility near Pittsburgh is operating with <a href=\"https://www.spglobal.com/platts/en/market-insights/latest-news/metals/061719-fire-knocks-out-desulfurization-equipment-at-us-steels-clariton-coke-facility\" target=\"_blank\">limited pollution controls</a> after a second fire in nearly six months broke out at the plant.</li><li>The Clairton facility, the biggest coke plant in the U.S., is more than 100 years old and one of the region's biggest polluters, and a Dec. 24 fire at the plant knocked out pollution controls, which sent sulfur dioxide emissions higher for several months.</li><li>Allegheny County health officials <a href=\"https://www.wsj.com/articles/u-s-steel-suffers-new-fire-knocking-out-pollution-controls-in-plant-near-pittsburgh-11560795102\" target=\"_blank\">warn residents</a> that people with respiratory problems, the elderly and children should again be aware of the potential for higher sulfur dioxide levels but do not issue any evacuation notice.</li><li>The company says the incident has not affected production at the facility.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471856\" data-linked=\"Fire knocks out pollution controls at U.S. Steel&#39;s Clariton coke plant\" data-tweet=\"$X - Fire knocks out pollution controls at U.S. Steel&#39;s Clariton coke plant https://seekingalpha.com/news/3471856-fire-knocks-out-pollution-controls-u-s-steels-clariton-coke-plant?source=tweet\" data-url=\"https://seekingalpha.com/news/3471856-fire-knocks-out-pollution-controls-u-s-steels-clariton-coke-plant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471855\" data-ts=\"1560797821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471855-themaven-makes-move-on-sports-illustrated-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TheMaven makes move on Sports Illustrated operations</a></h4><ul>   <li>TheMaven (<a href=\"http://seekingalpha.com/symbol/MVEN\" target=\"_blank\">MVEN</a> <font color=\"green\">+10.6%</font>) -- the nanocap coalition of digital content producers that just <a href=\"https://seekingalpha.com/news/3470832-thestreet-sale-closes-door-strategic-review-sell-offs\" target=\"_blank\">agreed to acquire TheStreet</a> -- is <a href=\"https://nypost.com/2019/06/17/sports-illustrateds-media-operations-just-got-sold-again/\" target=\"_blank\">taking over print and digital rights</a> for <i>Sports Illustrated,</i> also recently sold.</li>    <li>After buying the brand from Time Inc., Meredith (<a href=\"http://seekingalpha.com/symbol/MDP\" target=\"_blank\">MDP</a> <font color=\"green\">+1.5%</font>) last month <a href=\"https://seekingalpha.com/news/3466972-meredith-sells-sports-illustrated-110m\" target=\"_blank\">turned around and sold</a> <i>SI</i> to licensing firm Authentic Brands.</li>    <li>Authentic has now set a deal with TheMaven where the latter prepaid $45M to Authentic Brands against future royalties under a 10-year licensing deal.</li>    <li>Ross Levinsohn -- formerly of Tribune Interactive, Yahoo and Fox Interactive Media -- will join TheMaven as CEO of the <i>Sports Illustrated</i> media line.</li>    <li>And while Meredith loses the publishing rights, \u201cAs a result of ABG\u2019s decision to license the <i>Sports Illustrated</i> media assets to a third party \u2014 which was ABG\u2019s right under the contract \u2014 Meredith\u2019s goal of a completed transaction is achieved,\" it says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471855\" data-linked=\"TheMaven makes move on Sports Illustrated operations\" data-tweet=\"$MVEN $MDP - TheMaven makes move on Sports Illustrated operations https://seekingalpha.com/news/3471855-themaven-makes-move-on-sports-illustrated-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3471855-themaven-makes-move-on-sports-illustrated-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471853\" data-ts=\"1560797703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471853-ebix-eigi-and-dq-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EBIX, EIGI, and DQ among tech movers</a></h4><ul><li><strong>Gainers: </strong>Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"green\">+45%</font>. UP Fintech Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TIGR' title='UP Fintech Holding Limited'>TIGR</a>) <font color=\"green\">+28%</font>. Endurance International Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a>) <font color=\"green\">+24%</font>. AGM Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a>) <font color=\"green\">+21%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"green\">+14%</font>.</li> <li><strong>Losers: </strong>TuanChe Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-21%</font>. Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix, Inc.'>EBIX</a>) <font color=\"red\">-13%</font>. Daqo New Energy (NYSE:<a href='https://seekingalpha.com/symbol/DQ' title='Daqo New Energy Corp.'>DQ</a>) <font color=\"red\">-10%</font>. Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>) <font color=\"red\">-9%</font>. SeaChange International (NASDAQ:<a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471853\" data-linked=\"EBIX, EIGI, and DQ among tech movers\" data-tweet=\"$VISL $TIGR $EIGI - EBIX, EIGI, and DQ among tech movers https://seekingalpha.com/news/3471853-ebix-eigi-and-dq-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471853-ebix-eigi-and-dq-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471852\" data-ts=\"1560797339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471852-whirlpool-gains-after-strong-read-on-appliances-shipments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whirlpool gains after strong read on appliances shipments</a></h4><ul> <li>Shares of Whirlpool (<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a> <font color='green'>+2.2%</font>) track higher after AHAM data indicates <a href=\"http://www.aham.org/AHAM/What_We_Do/Industry_Data___Research/AHAM/What_We_Do/Industry_Data__Research.aspx?hkey=9cbf5066-987b-4cc5-8928-2f3a0da93e33\" target=\"_blank\">AHAM 6</a> shipments rose 9.9% in May compared to a year ago.</li> <li>The AHAM 6 category includes washers, dryers, dishwashers, refrigerators, freezers, ranges and ovens.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471852\" data-linked=\"Whirlpool gains after strong read on appliances shipments\" data-tweet=\"$WHR - Whirlpool gains after strong read on appliances shipments https://seekingalpha.com/news/3471852-whirlpool-gains-after-strong-read-on-appliances-shipments?source=tweet\" data-url=\"https://seekingalpha.com/news/3471852-whirlpool-gains-after-strong-read-on-appliances-shipments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471851\" data-ts=\"1560796667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQM\" target=\"_blank\">EQM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471851-eqm-ups-cost-delays-timing-of-mountain-valley-pipeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EQM ups cost, delays timing of Mountain Valley pipeline</a></h4><ul><li>EQM Midstream Partners (<a href='https://seekingalpha.com/symbol/EQM' title='EQM Midstream Partners, LP'>EQM</a> <font color='red'>-2.3%</font>) <a href=\"https://www.reuters.com/article/us-equitrans-mid-mountain-valley-natgas/eqm-raises-cost-delays-timing-of-mountain-valley-natural-gas-pipeline-idUSKCN1TI25E\" target=\"_blank\">raises the estimated cost</a> of its Mountain Valley natural gas pipeline from West Virginia to Virginia to $4.8B-$5B and delays the projected completion to mid-2020 due to legal and regulatory challenges.</li><li>EQM previously had estimated a $4.6B target cost to complete the project in Q4 2019.</li><li>The company says it submitted a land exchange proposal to the U.S. government in an effort to enable the pipe to cross the Appalachian Trail, which would grant the government full ownership of private lands crossed by the trail while granting Mountain Valley a right-of-way to cross the trail using the pipeline's previously planned underground method at an existing crossing location approved by the Federal Energy Regulatory Commission in 2017.</li><li>EQM says it will operate and fund ~$2.4B of Mountain Valley, which also is owned by units NextEra Energy (<a href='https://seekingalpha.com/symbol/NEE' title='NextEra Energy, Inc.'>NEE</a> <font color='red'>-0.1%</font>), Consolidated Edison (<a href='https://seekingalpha.com/symbol/ED' title='Consolidated Edison, Inc.'>ED</a> <font color='red'>-0.4%</font>), AltaGas (<a href='https://seekingalpha.com/symbol/ATGFF' title='AltaGas Ltd.'>OTCPK:ATGFF</a> <font color='green'>+0.2%</font>) and RGC Resources.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471851\" data-linked=\"EQM ups cost, delays timing of Mountain Valley pipeline\" data-tweet=\"$EQM $NEE $ED - EQM ups cost, delays timing of Mountain Valley pipeline https://seekingalpha.com/news/3471851-eqm-ups-cost-delays-timing-of-mountain-valley-pipeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3471851-eqm-ups-cost-delays-timing-of-mountain-valley-pipeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471850\" data-ts=\"1560796632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TER\" target=\"_blank\">TER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471850-teradata-taps-cisco-vet-cro\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teradata taps Cisco vet as CRO</a></h4><ul><li>Teradata (NASDAQ:<a href='https://seekingalpha.com/symbol/TER' title='Teradyne, Inc.'>TER</a>) <a href=\"https://seekingalpha.com/pr/17546542-teradata-appoints-scott-brown-chief-revenue-officer\" target=\"_blank\">appoints</a> Scott Brown as Chief Revenue Officer, effective June 17.</li><li>Brown most recently served as Cisco's SVP, Global Virtual Sales &amp; Customer Success.</li><li>TER shares are <font color=\"green\">up 1%</font> to $44.49.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471850\" data-linked=\"Teradata taps Cisco vet as CRO\" data-tweet=\"$TER - Teradata taps Cisco vet as CRO https://seekingalpha.com/news/3471850-teradata-taps-cisco-vet-cro?source=tweet\" data-url=\"https://seekingalpha.com/news/3471850-teradata-taps-cisco-vet-cro\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471849\" data-ts=\"1560795929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471849-morgan-stanley-warns-on-future-of-tobacco\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley warns on the future of tobacco</a></h4><ul> <li>Morgan Stanley sees the potential for the profitability of major tobacco companies to be reduced by as much as <a href=\"https://www.cnbc.com/2019/06/17/morgan-stanley-predicts-maximum-nicotine-policy-could-halve-tobacco-profits.html\" target=\"_blank\">50%</a>if the FDA adopts a \"maximum nicotine\" rule within the next 15 years, a risk it thinks isn't fully baked into share prices across the industry.</li> <li>\"Reducing nicotine in cigarettes to non-addictive or minimally addictive levels, in our view, would be a potential game changer for the U.S. industry,\" warns the firm.</li> <li>Morgan Stanley has Imperial Brands (<a href='https://seekingalpha.com/symbol/IMBBY' title='Imperial Brands PLC'>OTCQX:IMBBY</a> <font color='red'>-1.4%</font>) and Altria (<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a> <font color='green'>+0.4%</font>) rated at underweight and drops British American Tobacco (<a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c.'>BTI</a> <font color='red'>-1.3%</font>) to the same bearish stance.</li> <li>The long-term view from Morgan Stanley on tobacco is dim even with the max nicotine law off the table. MS forecasts the number of adult smokers in the U.S. to fall from 34M (~13% of population) in 2018 to 14M by 2030 (~5%) and then to less than 1% of the adult population by 2050.</li><li>Related: Philip Morris International (<a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a> <font color='green'>+1.7%</font>), Juul (<a href='https://seekingalpha.com/symbol/JUUL' title='JUUL'>JUUL</a>), Vector Group (<a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <font color='green'>+2.6%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471849\" data-linked=\"Morgan Stanley warns on the future of tobacco\" data-tweet=\"$IMBBY $MO $BTI - Morgan Stanley warns on the future of tobacco https://seekingalpha.com/news/3471849-morgan-stanley-warns-on-future-of-tobacco?source=tweet\" data-url=\"https://seekingalpha.com/news/3471849-morgan-stanley-warns-on-future-of-tobacco\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>267&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471848\" data-ts=\"1560795687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471848-applied-materialsminus-1_8-on-nomuras-cyclical-risk-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Materials -1.8% on Nomura&#39;s cyclical risk warning</a></h4><ul><li>Nomura maintains a Neutral rating and $40 PT for Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) but warns of risks that are \"high at the moment\" for AMAT and semis in general.</li><li>Analyst David Wong cites meetings with management when saying that AMAT expects a 2020 recovery but isn't \"predicting the slope of the recovery.\"</li><li>Wong praises AMAT's size and breadth and the services business, which \"has an important stabilizing effect.\"</li><li>AMAT shares are <font color=\"red\">down 1.8%</font> to $40.51.</li><li>Applied Materials has an Outperform average <a href=\"https://seekingalpha.com/symbol/AMAT/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471848\" data-linked=\"Applied Materials -1.8% on Nomura&#39;s cyclical risk warning\" data-tweet=\"$AMAT - Applied Materials -1.8% on Nomura&#39;s cyclical risk warning https://seekingalpha.com/news/3471848-applied-materialsminus-1_8-on-nomuras-cyclical-risk-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3471848-applied-materialsminus-1_8-on-nomuras-cyclical-risk-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471846\" data-ts=\"1560795553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPD\" target=\"_blank\">EPD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471846-enterprise-products-explores-sale-of-texas-oil-terminal-stake-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enterprise Products explores sale of Texas oil terminal stake - Reuters</a></h4><ul><li>Enterprise Products Partners (<a href='https://seekingalpha.com/symbol/EPD' title='Enterprise Products Partners L.P.'>EPD</a> <font color=\"red\">-1.4%</font>) is <a href=\"https://www.reuters.com/article/us-enterprise-prodt-crude-terminal-exclu/exclusive-enterprise-products-explores-sale-of-texas-oil-terminal-stake-document-idUSKCN1TI24D\" target=\"_blank\">seeking a sale of its 50% stake</a> in a joint venture with Plains All American Pipeline (<a href='https://seekingalpha.com/symbol/PAA' title='Plains All American Pipeline, L.P.'>PAA</a> <font color=\"red\">-2%</font>) for a recently-completed south Texas crude export terminal, Reuters reports.</li><li>The JV, Eagle Ford Terminals Corpus Christi, is connected to the two companies\u2019 660K bbl/day Eagle Ford JV Pipeline. which brings crude from the Permian Basin and Eagle Ford shale fields to the U.S. Gulf Coast.</li><li>In January, EPD filed to build its own deepwater export terminal, Sea Port of Texas, at a site 40 miles off the coast of Houston, where EPD has a much larger presence than Corpus Christi.</li><li>\"Enterprise is focusing on the Houston market,\" says Morningstar analyst Sandy Fielden, who also says it is not clear whether the terminal can compete with larger facilities being built in the Corpus Christi area.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471846\" data-linked=\"Enterprise Products explores sale of Texas oil terminal stake - Reuters\" data-tweet=\"$EPD $PAA - Enterprise Products explores sale of Texas oil terminal stake - Reuters https://seekingalpha.com/news/3471846-enterprise-products-explores-sale-of-texas-oil-terminal-stake-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3471846-enterprise-products-explores-sale-of-texas-oil-terminal-stake-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471843\" data-ts=\"1560794832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTN\" target=\"_blank\">RTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471843-raytheon-wins-234m-u-s-navy-contract-for-23-jpals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raytheon wins $234M U.S. Navy contract for 23 JPALS</a></h4><ul><li>Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color=\"green\">+0.9%</font>) has <a href=\"https://seekingalpha.com/pr/17546539-raytheon-wins-234-million-us-navy-contract-23-joint-precision-approach-landing-systems\" target=\"_blank\">secured</a> a four-year $234M initial low-rate production contract from the U.S. Navy to outfit all of its nuclear-powered aircraft carriers and amphibious assault ships with 23 Joint Precision Approach and Landing Systems &#40;JPALS&#41;.</li><li>JPALS is a GPS-based precision landing system that guides aircraft to precision landings in all weather and surface conditions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471843\" data-linked=\"Raytheon wins $234M U.S. Navy contract for 23 JPALS\" data-tweet=\"$RTN - Raytheon wins $234M U.S. Navy contract for 23 JPALS https://seekingalpha.com/news/3471843-raytheon-wins-234m-u-s-navy-contract-for-23-jpals?source=tweet\" data-url=\"https://seekingalpha.com/news/3471843-raytheon-wins-234m-u-s-navy-contract-for-23-jpals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471842\" data-ts=\"1560794690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBIX\" target=\"_blank\">EBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471842-ebix-questions-abnormal-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ebix questions abnormal trading</a></h4><ul><li>Ebix (<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix, Inc.'>EBIX</a> <font color='red'>-12.6%</font>) <a href=\"https://seekingalpha.com/pr/17546547-ebix-aware-news-events-tariffs-negatively-impact-business-account-today-s-abnormal-trading\" target=\"_blank\">announces</a> it's not aware of any news or <a href=\"https://seekingalpha.com/news/3471808-ebix-minus-11_6-percent-indian-tariffs\" target=\"_blank\">tariffs </a>that justifies today's \"abnormal trading activity.\"</li><li>The company says it remains confident in its FY18 growth outlook and its ability to achieve $800M+ in annualized quarterly revenue by Q4.</li><li>Ebix notes that its FY18 revenue rose 37% Y/Y to $497.8M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471842\" data-linked=\"Ebix questions abnormal trading\" data-tweet=\"$EBIX - Ebix questions abnormal trading https://seekingalpha.com/news/3471842-ebix-questions-abnormal-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3471842-ebix-questions-abnormal-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471841\" data-ts=\"1560794488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471841-on-c-and-j-energy-keane-merger-overall-energy-materials-shares-move-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">On C&amp;J Energy &amp; Keane merger, overall Energy/Materials shares move up</a></h4><ul><li><b>Gainers: </b>C&amp;J Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/CJ' title='C&J Energy Services, Inc.'>CJ</a>) <font color=\"green\">+25%</font>. Lonestar Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/LONE' title='Lonestar Resources US Inc.'>LONE</a>) <font color=\"green\">+17%</font>. Roan Resources (NYSE:<a href='https://seekingalpha.com/symbol/ROAN' title='Roan Resources, Inc.'>ROAN</a>) <font color=\"green\">+13%</font>. Keane Group (NYSE:<a href='https://seekingalpha.com/symbol/FRAC' title='Keane Group, Inc.'>FRAC</a>) <font color=\"green\">+12%</font>. Superior Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a>) <font color=\"green\">+10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471841\" data-linked=\"On C&amp;J Energy &amp; Keane merger, overall Energy/Materials shares move up\" data-tweet=\"$NEX $LONE $ROAN - On C&amp;J Energy &amp; Keane merger, overall Energy/Materials shares move up https://seekingalpha.com/news/3471841-on-c-and-j-energy-keane-merger-overall-energy-materials-shares-move-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3471841-on-c-and-j-energy-keane-merger-overall-energy-materials-shares-move-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471945\" data-ts=\"1560792718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUM\" target=\"_blank\">SUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471945-summit-shareholder-southeastern-asset-turns-active-11_4-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit shareholder Southeastern Asset turns active with 11.4% stake</a></h4><ul><li>Summit Materials (<a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials, Inc.'>SUM</a> <font color=\"green\">+8.7%</font>) is sharply higher after Southeastern Asset Management <a href=\"https://www.sec.gov/Archives/edgar/data/807985/000080798519000022/sum13d.txt\" target=\"_blank\">discloses a 12.8M-share position</a>, reflecting an 11.4% stake in the company, and changes its shareholding position to active from passive.</li><li>Southeastern says it is switching from a filing on Schedule 13G to Schedule 13D in order to have more direct conversations with SUM, other shareholders and interested third parties about opportunities to recognize the company's intrinsic value.</li><li>The news follows a report <a href=\"https://seekingalpha.com/news/3471135-colombian-firm-approaches-summit-materials-merger-reuters\" target=\"_blank\">last week</a> that Colombia's Cementos Argos had approached SUM about a potential merger.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471945\" data-linked=\"Summit shareholder Southeastern Asset turns active with 11.4% stake\" data-tweet=\"$SUM - Summit shareholder Southeastern Asset turns active with 11.4% stake https://seekingalpha.com/news/3471945-summit-shareholder-southeastern-asset-turns-active-11_4-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3471945-summit-shareholder-southeastern-asset-turns-active-11_4-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471836\" data-ts=\"1560792430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USB\" target=\"_blank\">USB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471836-vining-sparks-cuts-u-s-bancorp-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vining Sparks cuts U.S. Bancorp to outperform</a></h4><ul><li>U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-1%</font>) is cut to market outperform from strong buy by Vining Sparks analyst Marty L. Mosby.</li><li>Price target trimmed to $59 from $61, implying 13% upside potential.</li><li><a href=\"https://seekingalpha.com/symbol/USB/ratings/quant-ratings\" target=\"_blank\">Quant Rating </a>Neutral, <a href=\"https://seekingalpha.com/symbol/USB/ratings/sell-side-ratings\" target=\"_blank\">Sell-side average rating</a> Hold (4 Buy, 3 Outperform, 16 Hold, 2 Underperform, 1 Sell).</li><li>U.S. Bancorp<a href=\"https://seekingalpha.com/symbol/USB/momentum/performance\" target=\"_blank\"> three-month price performance</a> of 7.9% compares with 5.5% for sector median.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471836\" data-linked=\"Vining Sparks cuts U.S. Bancorp to outperform\" data-tweet=\"$USB - Vining Sparks cuts U.S. Bancorp to outperform https://seekingalpha.com/news/3471836-vining-sparks-cuts-u-s-bancorp-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3471836-vining-sparks-cuts-u-s-bancorp-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471835\" data-ts=\"1560792114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471835-biotech-outperforms-on-m-animal-spirits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotech outperforms on M&amp;A animal spirits</a></h4><ul><li>Array BioPharma is <font color=\"green\">up 56%</font> after <a href=\"https://seekingalpha.com/news/3471637-pfizer-acquire-array-biopharma\" target=\"_blank\">agreeing to a sale</a> to Pfizer for more than $10B. UniQuire, meanwhile, is <font color=\"green\">higher by 8.35% </font>after <a href=\"https://seekingalpha.com/news/3471653-uniqure-considering-potential-sale-bloomberg\" target=\"_blank\">a weekend report that</a> it's exploring a sale.</li><li>Other potential biotech targets: BioMarin (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color=\"green\">+4.2%</font>), bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"green\">+3.5%</font>),  Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color=\"green\">+3%</font>), Neurocrine Bio (<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color=\"green\">+2.5%</font>), Seattle Genetics (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color=\"green\">+4.8%</font>), Sarepta (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color=\"green\">+1.5%</font>).</li><li>The iShares Nasdaq Biotechnology ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color=\"green\">+2.9%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a>, <a href='https://seekingalpha.com/symbol/HQL' title='Tekla Life Sciences Investors'>HQL</a>, <a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>, <a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a>, <a href='https://seekingalpha.com/symbol/LABD' title='Direxion Daily S&P Biotech Bear 3x Shares ETF'>LABD</a>, <a href='https://seekingalpha.com/symbol/PBE' title='Invesco Dynamic Biotechnology & Genome Portfolio ETF'>PBE</a>, <a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a>, <a href='https://seekingalpha.com/symbol/BBC' title='BioShares Biotechnology Clinical Trials Fund'>BBC</a>, <a href='https://seekingalpha.com/symbol/BBP' title='BioShares Biotechnology Products Fund'>BBP</a>, <a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a>, <a href='https://seekingalpha.com/symbol/ZBIO' title='ProShares UltraPro Short NASDAQ Biotechnology ETF'>ZBIO</a>, <a href='https://seekingalpha.com/symbol/GNOM' title='Global X Genomics & Biotechnology ETF'>GNOM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3471835\" data-linked=\"Biotech outperforms on M&amp;A animal spirits\" data-tweet=\"$BMRN $BLUE $SAGE - Biotech outperforms on M&amp;A animal spirits https://seekingalpha.com/news/3471835-biotech-outperforms-on-m-animal-spirits?source=tweet\" data-url=\"https://seekingalpha.com/news/3471835-biotech-outperforms-on-m-animal-spirits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471833\" data-ts=\"1560791366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MWK\" target=\"_blank\">MWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471833-mohawk-crumbles-in-second-week-of-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mohawk crumbles in second week of trading</a></h4><ul> <li>Mohawk Group (<a href='https://seekingalpha.com/symbol/MWK' title='Mohawk Group Holdings, Inc.'>MWK</a> <font color='red'>-13.9%</font>) slumps to a post-IPO low of $7.06 to put shares almost 30% below the $10 mark where the IPO was priced last week.</li><li>The company originally set a pricing range of $14 to $16 on the IPO shares.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3471833\" data-linked=\"Mohawk crumbles in second week of trading\" data-tweet=\"$MWK - Mohawk crumbles in second week of trading https://seekingalpha.com/news/3471833-mohawk-crumbles-in-second-week-of-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3471833-mohawk-crumbles-in-second-week-of-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471831\" data-ts=\"1560791102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471831-cbl-associates-properties-among-financial-gainers-rmr-group-and-prosperity-bancshares-only\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBL &amp; Associates Properties among financial gainers, RMR Group and Prosperity Bancshares the only losers</a></h4><ul><li><b>Gainers:</b> CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"green\">+7%</font>. Office Properties Income Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/OPI' title='Office Properties Income Trust'>OPI</a>) <font color=\"green\">+7%</font>. Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties, Inc.'>IIPR</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> The RMR Group (NASDAQ:<a href='https://seekingalpha.com/symbol/RMR' title='The RMR Group Inc.'>RMR</a>) <font color=\"red\">-6%</font>. Prosperity Bancshares (NYSE:<a href='https://seekingalpha.com/symbol/PB' title='Prosperity Bancshares, Inc.'>PB</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471831\" data-linked=\"CBL &amp; Associates Properties among financial gainers, RMR Group and Prosperity Bancshares the only losers\" data-tweet=\"$CBL $OPI $IIPR - CBL &amp; Associates Properties among financial gainers, RMR Group and Prosperity Bancshares the only losers https://seekingalpha.com/news/3471831-cbl-associates-properties-among-financial-gainers-rmr-group-and-prosperity-bancshares-only?source=tweet\" data-url=\"https://seekingalpha.com/news/3471831-cbl-associates-properties-among-financial-gainers-rmr-group-and-prosperity-bancshares-only\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471830\" data-ts=\"1560791040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471830-broadwind-energy-and-summit-materials-among-industrial-gainers-triumph-group-and-fuel-tech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadwind Energy and Summit Materials among industrial gainers; Triumph Group and Fuel Tech among losers</a></h4><ul><li><b>Gainers: </b>Orion Group (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+9%</font>. Summit Materials (NYSE:<a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials, Inc.'>SUM</a>) <font color=\"green\">+6%</font>. Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+6%</font>. Broadwind Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/BWEN' title='Broadwind Energy, Inc.'>BWEN</a>) <font color=\"green\">+6%</font>. Sharps Compliance (NASDAQ:<a href='https://seekingalpha.com/symbol/SMED' title='Sharps Compliance Corp.'>SMED</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Armstrong Flooring (NYSE:<a href='https://seekingalpha.com/symbol/AFI' title='Armstrong Flooring, Inc.'>AFI</a>) <font color=\"red\">-11%</font>. Fuel Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/FTEK' title='Fuel Tech, Inc.'>FTEK</a>) <font color=\"red\">-10%</font>. Triumph Group (NYSE:<a href='https://seekingalpha.com/symbol/TGI' title='Triumph Group, Inc.'>TGI</a>) <font color=\"red\">-8%</font>. Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"red\">-7%</font>. Vertex Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/VTNR' title='Vertex Energy, Inc.'>VTNR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471830\" data-linked=\"Broadwind Energy and Summit Materials among industrial gainers; Triumph Group and Fuel Tech among losers\" data-tweet=\"$ORN $SUM $HEBT - Broadwind Energy and Summit Materials among industrial gainers; Triumph Group and Fuel Tech among losers https://seekingalpha.com/news/3471830-broadwind-energy-and-summit-materials-among-industrial-gainers-triumph-group-and-fuel-tech?source=tweet\" data-url=\"https://seekingalpha.com/news/3471830-broadwind-energy-and-summit-materials-among-industrial-gainers-triumph-group-and-fuel-tech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471829\" data-ts=\"1560791030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471829-teslaplus-4-sentiment-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla +4% as sentiment improves</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) is <font color=\"green\">up 4.42%</font> on the day after some <a href=\"https://www.forbes.com/sites/neilwinton/2019/06/17/german-competition-will-rebound-in-teslas-favor-report/#18383173745a\" target=\"_blank\">help</a> after from Hamburg continues to resonate. In a note published last week but still being circulated today, Berenberg Bank said worries about demand for Tesla vehicles could be overblown due to many of the issues being logistical in nature. The firm sees the wave of EV competition from German auto firms as actually positive for Tesla on the expectation its \"superior and cheaper\" technology will be on display.</li> <li>\"Demand support could ironically come from legacy car makers (mainly the Germans but including Jaguar Land Rover) increased electric vehicle marketing activities, as consumers ultimately discover Tesla's more competitive offering, on both technology and price,\" wrote analyst Alexander Haissel.</li> <li>There is also some Twitter drama to report on. Over the weekend, Elon Musk both attacked Tesla co-founder Martin Eberhard (then erased the tweet) and stated that he deleted his Twitter account (it's still there although quiet).</li> <li>Tesla trades at a five-week high.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471829\" data-linked=\"Tesla +4% as sentiment improves\" data-tweet=\"$TSLA - Tesla +4% as sentiment improves https://seekingalpha.com/news/3471829-teslaplus-4-sentiment-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3471829-teslaplus-4-sentiment-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>647&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471825\" data-ts=\"1560790500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471825-sprint-t-mobile-makes-little-sense-dish-involved-moffett\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint/T-Mobile makes (a little) more sense with Dish involved - Moffett</a></h4><ul>   <li>Dish Network's (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"green\">+4%</font>) new links to the proposed $26B merger of Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color=\"green\">+0.9%</font>) and T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color=\"green\">+0.2%</font>) make the deal look less \"crazy,\" analyst Craig Moffett says.</li>    <li>A <a href=\"https://seekingalpha.com/news/3471596-dish-pole-position-scoop-sprint-t-mobile-assets-wsj\" target=\"_blank\">Friday report</a> said that Dish was the presumed leader in picking up assets that would need to be shed in order for the two carriers to get approval for their merger. That followed reports that Dish chief Charlie Ergen <a href=\"https://seekingalpha.com/news/3471492-dish-network-still-pressing-case-sprint-t-mobile-merger\" target=\"_blank\">was in a meeting</a> with the heads of both the FCC and the Justice Dept.</li>    <li>At least Dish and any other bidders for divested assets from the deal would be better than bringing in Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color=\"green\">+0.8%</font>), Moffett writes: \"But the question that we can\u2019t get past is ... why in the world is T-Mobile still trying so hard?\"</li>    <li>A bad deal is worse than no deal at all, he suggests.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471825\" data-linked=\"Sprint/T-Mobile makes (a little) more sense with Dish involved - Moffett\" data-tweet=\"$DISH $S $TMUS - Sprint/T-Mobile makes (a little) more sense with Dish involved - Moffett https://seekingalpha.com/news/3471825-sprint-t-mobile-makes-little-sense-dish-involved-moffett?source=tweet\" data-url=\"https://seekingalpha.com/news/3471825-sprint-t-mobile-makes-little-sense-dish-involved-moffett\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471820\" data-ts=\"1560789824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471820-bid-arry-bhvn-and-ebix-among-notable-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BID, ARRY, BHVN and EBIX among notable midday movers</a></h4><ul><li><strong>Gainers: </strong>Sotheby's (NYSE:<a href='https://seekingalpha.com/symbol/BID' title='Sotheby&#39;s'>BID</a>) <font color=\"green\">+58%</font>. Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) <font color=\"green\">+57%</font>. ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+42%</font>. Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"green\">+40%</font>. MTech Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/MTEC' title='MTech Acquisition Corp.'>MTEC</a>) <font color=\"green\">+34%</font>. Endurance International Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a>) <font color=\"green\">+26%</font>. C&amp;J Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/CJ' title='C&J Energy Services, Inc.'>CJ</a>) <font color=\"green\">+24%</font>. Arbutus Biopharma Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corporation'>ABUS</a>) <font color=\"green\">+24%</font>. Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) <font color=\"green\">+23%</font>. Calithera Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences, Inc.'>CALA</a>) <font color=\"green\">+19%</font>.</li> <li><strong>Losers: </strong>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"red\">-65%</font>. Celyad SA (NASDAQ:<a href='https://seekingalpha.com/symbol/CYAD' title='Celyad SA'>CYAD</a>) <font color=\"red\">-29%</font>. Mohawk Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MWK' title='Mohawk Group Holdings, Inc.'>MWK</a>) <font color=\"red\">-15%</font>. Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"red\">-15%</font>. Biohaven Pharmaceutical Holding (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) <font color=\"red\">-13%</font>. Avadel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a>) <font color=\"red\">-13%</font>. AzurRx BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRx BioPharma, Inc.'>AZRX</a>) <font color=\"red\">-13%</font>. Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix, Inc.'>EBIX</a>) <font color=\"red\">-12%</font>. PaySign (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYS' title='PaySign, Inc.'>PAYS</a>) <font color=\"red\">-10%</font>. TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471820\" data-linked=\"BID, ARRY, BHVN and EBIX among notable midday movers\" data-tweet=\"$BID $ARRY $HEPA - BID, ARRY, BHVN and EBIX among notable midday movers https://seekingalpha.com/news/3471820-bid-arry-bhvn-and-ebix-among-notable-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471820-bid-arry-bhvn-and-ebix-among-notable-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471818\" data-ts=\"1560789671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIBB\" target=\"_blank\">HIBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471818-hibbett-sportsminus-5-after-disclosing-accounting-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hibbett Sports -5% after disclosing accounting delay</a></h4><ul> <li>Hibbett Sports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='red'>-5.1%</font>) trades lower after the retailer says it's delaying the filing of is 10-Q to review the recent adoption of the Financial Accounting Standards Board' new revisions.</li> <li>The 10-Q is anticipated to be filed shortly after the review is complete.</li> <li><a href=\"https://seekingalpha.com/filing/4533533\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3471818\" data-linked=\"Hibbett Sports -5% after disclosing accounting delay\" data-tweet=\"$HIBB - Hibbett Sports -5% after disclosing accounting delay https://seekingalpha.com/news/3471818-hibbett-sportsminus-5-after-disclosing-accounting-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3471818-hibbett-sportsminus-5-after-disclosing-accounting-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471816\" data-ts=\"1560789409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOW\" target=\"_blank\">DOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471816-dow-downgraded-bmo-on-global-trade-macro-growth-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dow downgraded at BMO on global trade, macro growth concerns</a></h4><ul><li>Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color=\"red\">-3.5%</font>) is near the bottom of today's S&amp;P 500 results after BMO Capital <a href=\"https://thefly.com/thestreet/realmoney/index.php/DOWid2922641/DOW-Dow-Inc-cut-to-Market-Perform-at-BMO-Capital-on-global-trade-issues\" target=\"_blank\">downgrades</a> shares to Market Perform from Outperform with a $52 price target, cut from $58, citing continuing global trade issues that are making for a more difficult macro environment.</li><li>BMO analyst John McNulty says while Dow remains among the \"diversified pure-play-commodity companies in the space\" with focus on shareholder value and led by \"solid\" management, 2019 is looking increasingly challenging for the company due to trade issues and faltering macro growth.</li><li>Given weakness in Silicons, MDI/TDI and PE markets, McNulty sees little short-term recovery and lowers his FY 2019 and FY 2020 EPS estimates to $3.99 and $4.82, respectively, from $4.41 and $5.60 previously.</li><li>DOW's average <a href=\"https://seekingalpha.com/symbol/DOW/ratings/sell-side-ratings\" target=\"_blank\">Selling Side Rating</a> is Outperform while its <a href=\"https://seekingalpha.com/symbol/DOW/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471816\" data-linked=\"Dow downgraded at BMO on global trade, macro growth concerns\" data-tweet=\"$DOW - Dow downgraded at BMO on global trade, macro growth concerns https://seekingalpha.com/news/3471816-dow-downgraded-bmo-on-global-trade-macro-growth-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3471816-dow-downgraded-bmo-on-global-trade-macro-growth-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471809\" data-ts=\"1560788061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471809-aegis-makes-bull-move-on-snap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegis makes a bull move on Snap</a></h4><ul>   <li>Aegis Capital has upgraded Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color=\"red\">-2.9%</font>) to Buy for the first time since before the company's IPO.</li>    <li>Analyst Victor Anthony notes less skepticism about the company's ability to drive user growth, pointing to boosts in engagement and advertiser interest. Snap's also \"largely absent\" from the privacy and antitrust woes that are boosting risk on the FAANGs, he writes.</li>    <li>He also says Snap shouldn't be looking for a buyer and can now \"stand on its own.\"</li>    <li>The firm has a price target of $17, implying 25% upside.</li>    <li>The bulk of analysts are on the sidelines: Sell-siders <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/sell-side-ratings\" target=\"_blank\">rate it Hold on average</a>, while <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors are Neutral</a> and its <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/quant-ratings\" target=\"_blank\">Quant Rating is Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471809\" data-linked=\"Aegis makes a bull move on Snap\" data-tweet=\"$SNAP - Aegis makes a bull move on Snap https://seekingalpha.com/news/3471809-aegis-makes-bull-move-on-snap?source=tweet\" data-url=\"https://seekingalpha.com/news/3471809-aegis-makes-bull-move-on-snap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471808\" data-ts=\"1560787960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBIX\" target=\"_blank\">EBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471808-ebixminus-11_6-on-indian-tariffs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ebix -11.6% on Indian tariffs</a></h4><ul><li>Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix, Inc.'>EBIX</a>) shares <font color=\"red\">plunge 11.6%</font> after an <a href=\"https://www.bloomberg.com/news/articles/2019-06-16/india-imposes-tariffs-on-u-s-goods-as-global-trade-war-heats-up\" target=\"_blank\">Indian tariff increase</a> on U.S. goods went into effect. The move followed the U.S. decision to end trade concessions.</li><li>Last year, about 39% of overall Ebix revenue came from India.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471808\" data-linked=\"Ebix -11.6% on Indian tariffs\" data-tweet=\"$EBIX - Ebix -11.6% on Indian tariffs https://seekingalpha.com/news/3471808-ebixminus-11_6-on-indian-tariffs?source=tweet\" data-url=\"https://seekingalpha.com/news/3471808-ebixminus-11_6-on-indian-tariffs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471803\" data-ts=\"1560787197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471803-beyond-meat-leads-consumer-gainers-sanderson-farms-and-kbs-fashion-group-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat leads consumer gainers; Sanderson Farms and KBS Fashion Group among losers</a></h4><ul><li><b>Gainers: </b>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"green\">+10%</font>. Lifeway Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/LWAY' title='Lifeway Foods, Inc.'>LWAY</a>) <font color=\"green\">+6%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Mohawk Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MWK' title='Mohawk Group Holdings, Inc.'>MWK</a>) <font color=\"red\">-13%</font>. KBS Fashion Group (NASDAQ:<a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a>) <font color=\"red\">-6%</font>. Sanderson Farms (NASDAQ:<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471803\" data-linked=\"Beyond Meat leads consumer gainers; Sanderson Farms and KBS Fashion Group among losers\" data-tweet=\"$BYND $LWAY $VFF - Beyond Meat leads consumer gainers; Sanderson Farms and KBS Fashion Group among losers https://seekingalpha.com/news/3471803-beyond-meat-leads-consumer-gainers-sanderson-farms-and-kbs-fashion-group-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471803-beyond-meat-leads-consumer-gainers-sanderson-farms-and-kbs-fashion-group-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471802\" data-ts=\"1560787118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIME\" target=\"_blank\">MIME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471802-mimecastplus-5_8-on-jefferies-top-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mimecast +5.8% on Jefferies&#39; top pick</a></h4><ul><li>Jefferies reiterates a Buy rating and $57 PT on Mimecast (NASDAQ:<a href='https://seekingalpha.com/symbol/MIME' title='Mimecast Limited'>MIME</a>) and taps the company as a \"top small cap pick.\"</li><li>The firm cites meetings with management and sees opportunities emerging in identity and the resiliency platform that others can leverage.</li><li>Mimecast shares are <font color=\"green\">up 5.8%</font> to $46.43.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471802\" data-linked=\"Mimecast +5.8% on Jefferies&#39; top pick\" data-tweet=\"$MIME - Mimecast +5.8% on Jefferies&#39; top pick https://seekingalpha.com/news/3471802-mimecastplus-5_8-on-jefferies-top-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3471802-mimecastplus-5_8-on-jefferies-top-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471800\" data-ts=\"1560786852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471800-deere-upgraded-baird-higher-demand-seen-for-farm-equipment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere upgraded at Baird as higher demand seen for farm equipment</a></h4><ul><li>Deere (<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color=\"green\">+1.4%</font>) powers higher after Baird <a href=\"https://www.thestreet.com/investing/stocks/deere-climbs-on-bullish-baird-note-14993108\" target=\"_blank\">upgrades shares to Outperform</a> from Neutral with a $175 price target, up from $129, saying the bad weather that has pushed up the price of corn and other  commodities also will prompt demand for farm equipment late this year and into 2020.</li><li>Corn prices and machinery demand are correlated, with machinery volumes usually on a one-year lag vs. corn prices, Baird says, also noting \"equipment purchases are a great tool for farmers to reduce tax liability which combines with already present replacement demand.\"</li><li>Only 83% of corn acres had been planted as of June 9, while 100% would be planted at this point during virtually every other year, meaning nearly 15M acres have yet to be planted, according to Baird.</li><li>DE's average <a href=\"https://seekingalpha.com/symbol/DE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while both the average <a href=\"https://seekingalpha.com/symbol/DE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/DE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471800\" data-linked=\"Deere upgraded at Baird as higher demand seen for farm equipment\" data-tweet=\"$DE - Deere upgraded at Baird as higher demand seen for farm equipment https://seekingalpha.com/news/3471800-deere-upgraded-baird-higher-demand-seen-for-farm-equipment?source=tweet\" data-url=\"https://seekingalpha.com/news/3471800-deere-upgraded-baird-higher-demand-seen-for-farm-equipment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471796\" data-ts=\"1560785773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471796-mosaic-upgraded-baml-long-term-potential-outweighs-short-term-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic upgraded at BAML as long-term potential outweighs short-term risks</a></h4><ul><li>Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='green'>+4.6%</font>) moves higher after BofA Merrill Lynch <a href=\"https://thefly.com/thestreet/realmoney/index.php/MOSid2922810/MOS-Mosaics-longerterm-potential-upside-outweighs-risks-says-BofAMerrill\" target=\"_blank\">upgrades shares to Buy</a> from Neutral, with analyst Steve Byrne saying he toured MOS's assets in Brazil last week and is \"comfortable\" with the uncertainty.</li><li>MOS shares are a third lower over the last four months due to a combination of earnings risks from the wet spring in the U.S., uncertainty associated with Brazilian tailings dams and a weaker pricing outlook for phosphate and potash, but analyst Steve Byrne believes the stock's longer-term potential upside outweighs near-term risks.</li><li>Byrne also says he is more constructive on the long-term outlook for Fertilizantes.</li><li>MOS's average <a href=\"https://seekingalpha.com/symbol/MOS/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its average <a href=\"https://seekingalpha.com/symbol/MOS/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> is Bullish, but <a href=\"https://seekingalpha.com/symbol/MOS/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471796\" data-linked=\"Mosaic upgraded at BAML as long-term potential outweighs short-term risks\" data-tweet=\"$MOS - Mosaic upgraded at BAML as long-term potential outweighs short-term risks https://seekingalpha.com/news/3471796-mosaic-upgraded-baml-long-term-potential-outweighs-short-term-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3471796-mosaic-upgraded-baml-long-term-potential-outweighs-short-term-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471793\" data-ts=\"1560785258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LK\" target=\"_blank\">LK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471793-luckin-rallies-sell-side-tailwind\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Luckin rallies with sell-side tailwind</a></h4><ul> <li>Luckin Coffee (NASDAQ:<a href='https://seekingalpha.com/symbol/LK' title='Luckin Coffee Inc.'>LK</a>) is <font color=\"green\">up 7.65%</font> on the day and 12% over the last week.</li> <li>Last week, Credit Suisse jumped in with an Outperform initiation on the Chinese coffee startup and CICC started off coverage with a Buy rating. Those bull calls came on top of <a href=\"https://seekingalpha.com/news/3470396-luckin-coffee-attracts-new-bulls\" target=\"_blank\">positive ratings</a> from Needham and KeyBanc. Overall, six out of seven firms <a href=\"https://seekingalpha.com/symbol/LK/ratings/sell-side-ratings\" target=\"_blank\">covering</a> Luckin are in the bull camp.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471793\" data-linked=\"Luckin rallies with sell-side tailwind\" data-tweet=\"$LK - Luckin rallies with sell-side tailwind https://seekingalpha.com/news/3471793-luckin-rallies-sell-side-tailwind?source=tweet\" data-url=\"https://seekingalpha.com/news/3471793-luckin-rallies-sell-side-tailwind\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471787\" data-ts=\"1560784597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471787-boeing-lifts-20-year-outlook-for-airplane-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing lifts 20-year outlook for airplane demand</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+1.9%</font>) is today's top DJIA gainer after the company <a href=\"https://boeing.mediaroom.com/2019-06-17-Boeing-Forecasts-8-7-Trillion-Aerospace-and-Defense-Market-through-2028\" target=\"_blank\">raised its rolling 20-year global demand forecast</a> for passenger aircraft by 3%, fueled by strong air traffic predictions.</li><li>Boeing says the airline industry will need ~44K new commercial aircraft worth $6.8T by 2038, vs. 43K planes worth $6.49T estimated last year, with the biggest demand in single-aisle jets, where the company estimates airlines will need to make 32,420 narrow-body planes by 2038.</li><li>The forecast is underpinned by a prediction for average global traffic growth of 4.6%, down from 4.7% projected a year ago.</li><li>In the wide-body segment, Boeing also foresees demand for 8,340 new wide-body planes valued at more than $2.T over the next two decades, up 270 from the 8,070 it forecast last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471787\" data-linked=\"Boeing lifts 20-year outlook for airplane demand\" data-tweet=\"$BA - Boeing lifts 20-year outlook for airplane demand https://seekingalpha.com/news/3471787-boeing-lifts-20-year-outlook-for-airplane-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3471787-boeing-lifts-20-year-outlook-for-airplane-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471784\" data-ts=\"1560784325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471784-meetplus-4-roth-refutes-short-seller-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet +4% as Roth refutes short-seller report</a></h4><ul><li>The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <font color=\"green\">gains 4.2% </font>after Roth defends the company after last week's <a href=\"https://seekingalpha.com/news/3471543-meet-group-refutes-short-seller-report\" target=\"_blank\">short-seller report</a>.</li><li>Analyst Darren Aftahi says that while \"MEET\u2019s business has risks, we don\u2019t believe these risks are unique to it, as all digital platforms have inherent risks.\"</li><li>He also notes that Meet Group \"has taken a proactive stance towards safety and regulation on its platform,\" which was the backbone of Meet's own response to the report.</li><li>Roth maintains a Buy rating and $8 PT.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471784\" data-linked=\"Meet +4% as Roth refutes short-seller report\" data-tweet=\"$MEET - Meet +4% as Roth refutes short-seller report https://seekingalpha.com/news/3471784-meetplus-4-roth-refutes-short-seller-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3471784-meetplus-4-roth-refutes-short-seller-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471783\" data-ts=\"1560784152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471783-beyond-meatplus-9-after-pulling-off-another-mainstream-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat +9% after pulling off another mainstream move</a></h4><ul> <li>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) is <font color=\"green\">up 8.55%</font> on morning volume of over 5M shares.</li> <li>The latest twist from the alternative protein company is that it will start <a href=\"https://www.cnn.com/2019/06/17/business/beyond-meat-ground-beef/index.html\" target=\"_blank\">selling</a> plant-based \"ground beef\" on June 24 at Whole Foods, Wegmans, HEB and Atlanta-area Kroger stores.</li> <li>Beyond Meat calls the product \"versatile enough\" to use in ground beef recipe like meatballs or taco meat. The company has benefited from a number of reviews from skeptics who stated they were surprised at how close the BYND meatless products taste to the real thing, although the market valuation is worrying many on Wall Street.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471783\" data-linked=\"Beyond Meat +9% after pulling off another mainstream move\" data-tweet=\"$BYND - Beyond Meat +9% after pulling off another mainstream move https://seekingalpha.com/news/3471783-beyond-meatplus-9-after-pulling-off-another-mainstream-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3471783-beyond-meatplus-9-after-pulling-off-another-mainstream-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>100&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471779\" data-ts=\"1560783723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471779-array-biopharma-leads-healthcare-gainers-india-globalization-capital-and-avadel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array BioPharma leads healthcare gainers; India Globalization Capital and Avadel Pharmaceuticals among losers</a></h4><ul><li><b>Gainers: </b>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) <font color=\"green\">+56%</font>. ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+49%</font>. Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) <font color=\"green\">+21%</font>. Turning Point Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TPTX' title='Turning Point Therapeutics, Inc.'>TPTX</a>) <font color=\"green\">+18%</font>. Enlivex Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ENLV' title='Enlivex Therapeutics Ltd.'>ENLV</a>) <font color=\"green\">+14%</font>.</li><li><b>Losers: </b>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"red\">-61%</font>. Celyad (NASDAQ:<a href='https://seekingalpha.com/symbol/CYAD' title='Celyad SA'>CYAD</a>) <font color=\"red\">-27%</font>. Bionano Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/BNGO' title='Bionano Genomics, Inc.'>BNGO</a>) <font color=\"red\">-13%</font>. India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"red\">-12%</font>. Avadel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471779\" data-linked=\"Array BioPharma leads healthcare gainers; India Globalization Capital and Avadel Pharmaceuticals among losers\" data-tweet=\"$ARRY $HEPA $VSTM - Array BioPharma leads healthcare gainers; India Globalization Capital and Avadel Pharmaceuticals among losers https://seekingalpha.com/news/3471779-array-biopharma-leads-healthcare-gainers-india-globalization-capital-and-avadel?source=tweet\" data-url=\"https://seekingalpha.com/news/3471779-array-biopharma-leads-healthcare-gainers-india-globalization-capital-and-avadel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471772\" data-ts=\"1560783409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471772-target-falls-after-rough-tech-weekend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target falls after rough tech weekend</a></h4><ul> <li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) is <font color=\"red\">down 1.25%</font> after a systems outage over the weekend reminded some investors of the retailer's tech mishaps of the past.</li> <li>Target blamed payments vendor NCR (<a href='https://seekingalpha.com/symbol/NCR' title='NCR Corporation'>NCR</a> <font color='red'>-1.1%</font>) for a 90-minute outage on Sunday and said Saturday's problems were tied to an internal technology issue.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471772\" data-linked=\"Target falls after rough tech weekend\" data-tweet=\"$TGT $NCR - Target falls after rough tech weekend https://seekingalpha.com/news/3471772-target-falls-after-rough-tech-weekend?source=tweet\" data-url=\"https://seekingalpha.com/news/3471772-target-falls-after-rough-tech-weekend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471768\" data-ts=\"1560782819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEON\" target=\"_blank\">VEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471768-veonplus-2_7-ubs-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veon +2.7% as UBS boosts to Buy</a></h4><ul>   <li>Veon ADRs (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd.'>VEON</a>) are <font color=\"green\">up 2.9%</font> after an upgrade to Buy at UBS, from Neutral.</li>    <li>The ADRs have been rangebound (but with some healthy swings along the way), <font color=\"red\">down 2.8%</font> over the past six months and <font color=\"green\">up 1.7%</font> over the past 12 months.</li>    <li>Sell-siders on average <a href=\"https://seekingalpha.com/symbol/VEON/ratings/sell-side-ratings\" target=\"_blank\">rate the shares an Outperform</a>, while <a href=\"https://seekingalpha.com/symbol/VEON/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors are Bearish overall</a> and Veon has a <a href=\"https://seekingalpha.com/symbol/VEON/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Bullish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471768\" data-linked=\"Veon +2.7% as UBS boosts to Buy\" data-tweet=\"$VEON - Veon +2.7% as UBS boosts to Buy https://seekingalpha.com/news/3471768-veonplus-2_7-ubs-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3471768-veonplus-2_7-ubs-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471762\" data-ts=\"1560781994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFUN\" target=\"_blank\">SFUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471762-fang-holdingsplus-4_2-q1-operating-loss-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fang Holdings +4.2% as Q1 operating loss improves</a></h4><ul><li>Fang Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Limited'>SFUN</a>)<font color=\"green\"> jumps 4.2% </font>after<a href=\"https://seekingalpha.com/pr/17545731-fang-announces-first-quarter-2019-results\" target=\"_blank\"> Q1 operating loss </a>of $2.0M narrowed from its operating loss of $3.9M in the year-ago period as cost of sales declined.</li><li>Q1 total revenue of $51.9M fell 20% Y/Y; cost of revenue declined to $11.5M from $20.6M.</li><li>Q1 net income of $13.4M, or 15 cents per ordinary share, compares with net loss of $44.9M, or loss of 51 cents per share, in the year-ago quarter.</li><li>The current quarter includes realized gain on sale of available-for-sale securities of $299M and gain on change in fair value of securities of $32.1M.</li><li>Q1 non-GAAP net loss of $9.89M widened from a loss of $9.35M a year ago; on a per-share basis, non-GAAP loss was 11 cents vs. non-GAAP EPS of 2 cents a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3471630-fang-holdings-reports-q1-results\" target=\"_blank\">Fang Holdings reports Q1 results</a> (June 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3471762\" data-linked=\"Fang Holdings +4.2% as Q1 operating loss improves\" data-tweet=\"$SFUN - Fang Holdings +4.2% as Q1 operating loss improves https://seekingalpha.com/news/3471762-fang-holdingsplus-4_2-q1-operating-loss-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3471762-fang-holdingsplus-4_2-q1-operating-loss-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471761\" data-ts=\"1560781702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PS\" target=\"_blank\">PS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471761-pluralsight-understated-2018-net-loss-psplus-6_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluralsight understated 2018 net loss; PS +6.4%</a></h4><ul><li>Pluralsight (NASDAQ:<a href='https://seekingalpha.com/symbol/PS' title='Pluralsight, Inc.'>PS</a>) <a href=\"https://seekingalpha.com/filing/4534347\" target=\"_blank\">announces</a> that its 10-K for the year ending December 2018 and the quarterly reports ending June 30 and September 30 of that year contained an understatement of non-cash equity-based compensation, which led to an understated net loss.</li><li>The company says the mistakes were found to be unintentional and not the result of fraud.</li><li>For the impacted year, PS expects the net loss to increase by $18.2M.</li><li>Q2 guidance reaffirmed at $73.5-74M in revenue with adjusted loss per share of $0.15 to $0.13. The FY outlook has revenue of $312-318M with a loss per share of $0.48 to $0.38.</li><li>Pluralsight shares are <font color=\"green\">up 6.4%</font> to $31.91.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471761\" data-linked=\"Pluralsight understated 2018 net loss; PS +6.4%\" data-tweet=\"$PS - Pluralsight understated 2018 net loss; PS +6.4% https://seekingalpha.com/news/3471761-pluralsight-understated-2018-net-loss-psplus-6_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3471761-pluralsight-understated-2018-net-loss-psplus-6_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471760\" data-ts=\"1560781494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471760-contravir-pharma-encouraged-liver-disease-treatment-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir Pharma encouraged by liver disease treatment results</a></h4><ul><li>ContraVir Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color=\"green\">+40%</font>) surges after reporting \"<a href=\"https://seekingalpha.com/pr/17545982-compelling-positive-results-reported-human-liver-experiments-contravir-pharmaceuticals-nash\" target=\"_blank\">compelling positive results</a>\" from experiments involving the company's CRV431 drug candidate for the treatment of liver disease arising from non-alcoholic steatohepatitis and chronic viral infection.</li><li>CTRV says co-administration of CRV431 was found to be 100% effective at preventing fibrosis induction beyond baseline levels and at clinically relevant concentrations also partially or completely blocked several genetic and protein biomarkers of inflammation.</li><li>\"Precision cut liver slices adds to the growing list of experiments where CRV431 has demonstrated effectiveness and gives us great confidence in developing CRV431 for NASH and other liver diseases,\" the company says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471760\" data-linked=\"ContraVir Pharma encouraged by liver disease treatment results\" data-tweet=\"$CTRV $HEPA - ContraVir Pharma encouraged by liver disease treatment results https://seekingalpha.com/news/3471760-contravir-pharma-encouraged-liver-disease-treatment-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3471760-contravir-pharma-encouraged-liver-disease-treatment-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471759\" data-ts=\"1560781334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNTY\" target=\"_blank\">CNTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471759-century-casinosplus-13-after-casino-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Century Casinos +13% after casino deal</a></h4><ul> <li>Century Casinos (<a href='https://seekingalpha.com/symbol/CNTY' title='Century Casinos, Inc.'>CNTY</a> <font color='green'>+13%</font>) jumps after the company strikes a deal to acquire three casinos from Eldorado Resorts.</li> <li>\"Cape Girardeau, Caruthersville and Mountaineer expand the strategic diversity of Century Casinos with attractive assets in strong, stable markets. The expected increase to our free cash flow will allow us to remain well positioned to reduce leverage and evaluate additional strategic growth opportunities,\" states Century Co-CEO Erwin Haitzmann.</li><li>Shares of CNTY carved out a new multi-year high of $10.24 earlier in the session.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471759\" data-linked=\"Century Casinos +13% after casino deal\" data-tweet=\"$CNTY - Century Casinos +13% after casino deal https://seekingalpha.com/news/3471759-century-casinosplus-13-after-casino-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3471759-century-casinosplus-13-after-casino-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471756\" data-ts=\"1560781101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTWO\" target=\"_blank\">TTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471756-take-twoplus-1_2-benchmark-raises-target-on-ip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two +1.2% as Benchmark raises target on IP</a></h4><ul>   <li>Take-Two Interactive Software (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>)  is <font color=\"green\">up 1.2%</font> after Benchmark raised its price target on enthusiasm for the company's game portfolio and following a positive reaction at the E3 gaming expo.</li>    <li>The company has \"significant cash balance over no debt, strong free cash flow and share repurchases\" to go along with its very strong intellectual property, analyst Mike Hickey says.</li>    <li>And at E3, the company's <i>Borderlands 3</i> game got a \"jubilant\" reception, he notes.</li>    <li>He's raised his price target to $130 from $124, implying 17% upside.</li>    <li>Sell-side analysts on average <a href=\"https://seekingalpha.com/symbol/TTWO/ratings/sell-side-ratings\" target=\"_blank\">rate the stock a Buy</a>, while <a href=\"https://seekingalpha.com/symbol/TTWO/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors are Neutral</a> and it has a <a href=\"https://seekingalpha.com/symbol/TTWO/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471756\" data-linked=\"Take-Two +1.2% as Benchmark raises target on IP\" data-tweet=\"$TTWO - Take-Two +1.2% as Benchmark raises target on IP https://seekingalpha.com/news/3471756-take-twoplus-1_2-benchmark-raises-target-on-ip?source=tweet\" data-url=\"https://seekingalpha.com/news/3471756-take-twoplus-1_2-benchmark-raises-target-on-ip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471752\" data-ts=\"1560780804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWEN\" target=\"_blank\">BWEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471752-broadwind-energy-receives-29m-in-orders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadwind Energy receives $29M in orders</a></h4><ul><li>Broadwind Energy (<a href='https://seekingalpha.com/symbol/BWEN' title='Broadwind Energy, Inc.'>BWEN</a> <font color=\"green\">+7.2%</font>) <a href=\"https://seekingalpha.com/pr/17545818-broadwind-energy-announces-29-million-new-tower-orders\" target=\"_blank\">announces</a> $29M of new tower orders from multiple customers for production scheduled in 4Q19 through 2020.</li><li>\u201cWe are excited to announce new tower orders and the expansion of our tower customer base. We have made meaningful progress on our diversification strategy, recording $32M of diverse orders in 2019 against our $60M full year target\u201d, stated Stephanie Kushner, President and CEO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471752\" data-linked=\"Broadwind Energy receives $29M in orders\" data-tweet=\"$BWEN - Broadwind Energy receives $29M in orders https://seekingalpha.com/news/3471752-broadwind-energy-receives-29m-in-orders?source=tweet\" data-url=\"https://seekingalpha.com/news/3471752-broadwind-energy-receives-29m-in-orders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471740\" data-ts=\"1560779287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESLT\" target=\"_blank\">ESLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471740-elbit-systems-secures-50m-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elbit Systems secures $50M contract</a></h4><ul><li>Elbit Systems (<a href='https://seekingalpha.com/symbol/ESLT' title='Elbit Systems Ltd.'>ESLT</a> <font color=\"red\">-0.6%</font>) subsidiary, Elbit Systems - Cyclone Ltd., has been <a href=\"https://seekingalpha.com/pr/17545537-elbit-systems-awarded-50-million-contract-supply-structural-parts-fromcomposite-materials\" target=\"_blank\">awarded</a> an ~$50M contract for the supply of structural parts from composite materials for an aircraft of a customer in North America.</li><li>The contract will be performed over six years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471740\" data-linked=\"Elbit Systems secures $50M contract\" data-tweet=\"$ESLT - Elbit Systems secures $50M contract https://seekingalpha.com/news/3471740-elbit-systems-secures-50m-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3471740-elbit-systems-secures-50m-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471739\" data-ts=\"1560779228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EB\" target=\"_blank\">EB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471739-eventbriteplus-9_7-new-bull-sees-growth-pathway\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eventbrite +9.7% as new bull sees growth pathway</a></h4><ul><li>William Blair starts Eventbrite (NYSE:<a href='https://seekingalpha.com/symbol/EB' title='Eventbrite, Inc.'>EB</a>) at Outperform and becomes the second Buy-equivalent rating for the company.</li><li>The firm see \"a long pathway for growth\" and thinks investor expectations have been tempered by the Ticketfly migration.</li><li>Blair also cites the current valuation with shares down nearly 60% from the September highs.</li><li>Eventbrite shares are <font color=\"green\">up 9.7%</font> to $17.57.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471739\" data-linked=\"Eventbrite +9.7% as new bull sees growth pathway\" data-tweet=\"$EB - Eventbrite +9.7% as new bull sees growth pathway https://seekingalpha.com/news/3471739-eventbriteplus-9_7-new-bull-sees-growth-pathway?source=tweet\" data-url=\"https://seekingalpha.com/news/3471739-eventbriteplus-9_7-new-bull-sees-growth-pathway\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471737\" data-ts=\"1560779165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BID\" target=\"_blank\">BID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471737-sothebys-skies-after-buyout-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sotheby&#39;s skies after buyout offer</a></h4><ul> <li>Sotheby's (NYSE:<a href='https://seekingalpha.com/symbol/BID' title='Sotheby&#39;s'>BID</a>) opens <font color=\"green\">up 56.99%</font> to $55.56 to fall just a bit short of the $57 offer price from Patrick Drahi's BidFair USA.</li> <li>CNBC's David Faber reports that Sotheby's has been working on a deal for a while. The merger terms allow for a normal \"go-shop\" period for Sotheby's.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3471715-sothebys-goes-private-60-percent-premium\" target=\"_blank\">Sotheby's goes private for 60% premium</a> (June 17)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471737\" data-linked=\"Sotheby&#39;s skies after buyout offer\" data-tweet=\"$BID - Sotheby&#39;s skies after buyout offer https://seekingalpha.com/news/3471737-sothebys-skies-after-buyout-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3471737-sothebys-skies-after-buyout-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471723\" data-ts=\"1560777649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471723-baidus-target-cut-on-heavy-feed-spend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu&#39;s target cut on &#39;heavy&#39; feed spend</a></h4><ul><li>Bernstein lowers its Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) target from $180 to $130 and maintains a Market Perform.</li><li>The firm says the \"heavy investment in feed is value destructive\" and Baidu \"should stick with the core business in search going forward.\"</li><li>Bernstein says Baidu still has a \"dominant position in search and a strong balance sheet.\"</li><li>BIDU shares are <font color=\"red\">down 0.3%</font> pre-market to $112.71.</li><li>Baidu has an Outperform <a href=\"https://seekingalpha.com/symbol/BIDU/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471723\" data-linked=\"Baidu&#39;s target cut on &#39;heavy&#39; feed spend\" data-tweet=\"$BIDU - Baidu&#39;s target cut on &#39;heavy&#39; feed spend https://seekingalpha.com/news/3471723-baidus-target-cut-on-heavy-feed-spend?source=tweet\" data-url=\"https://seekingalpha.com/news/3471723-baidus-target-cut-on-heavy-feed-spend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471721\" data-ts=\"1560777577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471721-nucor-sees-below-consensus-q2-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucor sees below-consensus Q2 earnings</a></h4><ul><li>Nucor (NYSE:<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a>) <font color=\"red\">-3.8%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17546167-nucor-announces-guidance-second-quarter-2019-earnings\" target=\"_blank\">guiding Q2 earnings of $1.20-$1.25</a>, well below Q1 and year-ago results as well as Wall Street expectations.</li><li>NUE's anticipated Q2 range is below Q1 earnings of $1.63/share and Q2 2018 EPS of $2.13, and the analyst consensus EPS estimate for the quarter is $1.49.</li><li>NUE expects Q2 performance in its steel mills segment to decrease relative to Q1 as  service center destocking is impacting order rates, as increased domestic supply and a declining scrap price environment have led to aggressive inventory management by customers.</li><li>The company expects profitability of its steel products segment to improve Q/Q, as typical seasonal patterns and improved weather conditions have  benefited non-residential construction markets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471721\" data-linked=\"Nucor sees below-consensus Q2 earnings\" data-tweet=\"$NUE - Nucor sees below-consensus Q2 earnings https://seekingalpha.com/news/3471721-nucor-sees-below-consensus-q2-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3471721-nucor-sees-below-consensus-q2-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471717\" data-ts=\"1560777370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471717-suntrust-sees-major-move-for-facebook-in-crypto-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust sees major move for Facebook in crypto plans</a></h4><ul>   <li>On the verge of the <a href=\"https://seekingalpha.com/news/3471296-visa-mastercard-paypal-uber-board-facebook-cryptocurrency-wsj\" target=\"_blank\">release of a cryptocurrency whitepaper</a> by Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook, Inc.'>FB</a>), SunTrust Robinson Humphrey characterizes the move as potentially \"dramatically\" expanding the company's total addressable market and growth prospects.</li>    <li>Facebook's approach to a new digital token indicates its intent to become a transaction platform, the firm says. It sets Facebook up as \"one of the key actors at the center of the crypto currency development, and a main architect of the future of this emerging and important trend.\"</li>    <li>The firm has a Buy rating on Facebook with a price target of $215, implying 18.6% upside.</li>    <li>Bitcoin <a href=\"https://seekingalpha.com/news/3471615-bitcoin-tops-9k-facebook-crypto-plans\" target=\"_blank\">crested $9,000</a> for the first time since May 2018 yesterday.</li>    <li>Facebook is <font color=\"green\">up 1.8%</font> premarket. Meanwhile, stocks with links to cryptocurrencies are higher premarket: Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) is <font color=\"green\">up 12.1%</font>; Grayscale Bitcoin Trust (<a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>) <font color=\"green\">up 10.6%</font>; Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">up 5%</font>; Xunlei Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"green\">up 4.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471717\" data-linked=\"SunTrust sees major move for Facebook in crypto plans\" data-tweet=\"$FB $RIOT $GBTC - SunTrust sees major move for Facebook in crypto plans https://seekingalpha.com/news/3471717-suntrust-sees-major-move-for-facebook-in-crypto-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3471717-suntrust-sees-major-move-for-facebook-in-crypto-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471713\" data-ts=\"1560777035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471713-arry-riot-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ARRY, RIOT among premarket gainers</a></h4><ul><li>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+71%</font> on <a href=\"https://seekingalpha.com/pr/17545982-compelling-positive-results-reported-human-liver-experiments-contravir-pharmaceuticals-nash\" target=\"_blank\">positive results</a> reported from Human Liver experiments with ContraVir Pharmaceuticals\u2019 nash drug candidate.</li><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) <font color=\"green\">+60%</font> on <a href=\"https://seekingalpha.com/news/3471637-pfizer-acquire-array-biopharma\" target=\"_blank\">acquiring</a> Array Biopharma.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+12%</font>.</li><li>uniQure N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a>) <font color=\"green\">+8%</font> on considering <a href=\"https://seekingalpha.com/news/3471653-uniqure-considering-potential-sale-bloomberg\" target=\"_blank\">potential sale </a>- Bloomberg.</li><li>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"green\">+7%</font>.</li><li>NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"green\">+5%</font>.</li><li>Hemispherx Biopharma (NYSEMKT:<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/pr/17546061-hemispherx-biopharma-issues-clinical-update-ampligen-immuno-oncology-program\" target=\"_blank\">clinical update</a> for Ampligen immuno-oncology program.</li><li>Fiverr International (NYSE:<a href='https://seekingalpha.com/symbol/FVRR' title='Fiverr International Ltd.'>FVRR</a>) <font color=\"green\">+5%</font>.</li><li>ReWalk Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics Ltd.'>RWLK</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471713\" data-linked=\"ARRY, RIOT among premarket gainers\" data-tweet=\"$HEPA $ARRY $RIOT - ARRY, RIOT among premarket gainers https://seekingalpha.com/news/3471713-arry-riot-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471713-arry-riot-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471712\" data-ts=\"1560776951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471712-vbiv-and-htgm-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBIV and HTGM among premarket losers</a></h4><ul><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"red\">-54%</font> on <a href=\"https://seekingalpha.com/news/3471677-vbis-hepatitis-b-vaccine-meets-primary-goals\" target=\"_blank\">announcing</a> top-line results from PROTECT, a Phase 3 Study of Sci-B-Vac.</li><li>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) <font color=\"red\">-9%</font>.</li><li>HTG Molecular Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics, Inc.'>HTGM</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471712\" data-linked=\"VBIV and HTGM among premarket losers\" data-tweet=\"$VBIV $OTLK $HTGM - VBIV and HTGM among premarket losers https://seekingalpha.com/news/3471712-vbiv-and-htgm-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3471712-vbiv-and-htgm-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471711\" data-ts=\"1560776863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VYGR\" target=\"_blank\">VYGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471711-voyager-therapeutics-to-restructure-sanofi-gene-therapy-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Voyager Therapeutics to restructure Sanofi gene therapy deal</a></h4><ul><li>Voyager Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics, Inc.'>VYGR</a>) <font color=\"red\">-3.4%</font> pre-market on news it is <a href=\"https://seekingalpha.com/pr/17545853-voyager-therapeutics-announces-restructured-gene-therapy-relationship-sanofi-genzyme\" target=\"_blank\">restructuring its gene therapy relationship</a> with Sanofi Genzyme (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>).</li><li>VYGR says it will gain worldwide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program, while VYGR will transfer the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a>).</li><li>Sanofi Genzyme will obtain exclusive option rights to select novel AAV capsids owned or controlled by VYGR for exclusive use for up to two non-central nervous system indications.</li><li>To focus its resources on the now wholly-owned Huntington's disease program, VYGR says it will seek a partner to advance its pre-clinical program for SOD1 amyotrophic lateral sclerosis and will not file an IND application for VY-SOD102 in 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471711\" data-linked=\"Voyager Therapeutics to restructure Sanofi gene therapy deal\" data-tweet=\"$VYGR $SNY $NBIX - Voyager Therapeutics to restructure Sanofi gene therapy deal https://seekingalpha.com/news/3471711-voyager-therapeutics-to-restructure-sanofi-gene-therapy-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3471711-voyager-therapeutics-to-restructure-sanofi-gene-therapy-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471709\" data-ts=\"1560776788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XERS\" target=\"_blank\">XERS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471709-xeris-reports-positive-trial-results-for-rtu-glucagon-in-hypoglycemia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xeris reports positive trial results for RTU glucagon in hypoglycemia</a></h4><ul><li>Xeris Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/XERS' title='Xeris Pharmaceuticals, Inc.'>XERS</a>) ready-to-use glucagon auto-injector <a href=\"https://seekingalpha.com/pr/17545878-xeris-pharmaceuticals-announces-additional-positive-outcomes-global-phase-3-clinical-trial\" target=\"_blank\">showed comparable </a>efficacy with Novo Nordisk's GlucaGen HypoKit for achieving plasma glucose of greater than 70 mg/dl or greater than or equal to 20 mg/dl increase in glucose concentration within 30 minutes of glucogon administration in a Phase 3 non-inferiority study in Europe and North America.</li><li>Xeris <font color=\"green\">gains 0.7%</font> to in $9.61 premarket trading.</li><li>Study conducted among 132 adults with type 1 diabetes to evaluate the Xeris RTU glucagon auto-injector as a treatment for severe hypoglycemic events.</li><li>Study also found that time to resolution of hypoglycemia symptoms as well as time to resolution of the overall feeling of hypoglycemia was comparable between Xeris RTU glucagon and the marketed emergency kit.</li><li>Overall, no safety or tolerability concerns were noted.</li><li>NDA for the investigational product, to be branded Gvoke HypoPen in the U.S., is currently under review with the U.S. Food and Drug Administration, with a decision expected Sept. 10, 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471709\" data-linked=\"Xeris reports positive trial results for RTU glucagon in hypoglycemia\" data-tweet=\"$XERS - Xeris reports positive trial results for RTU glucagon in hypoglycemia https://seekingalpha.com/news/3471709-xeris-reports-positive-trial-results-for-rtu-glucagon-in-hypoglycemia?source=tweet\" data-url=\"https://seekingalpha.com/news/3471709-xeris-reports-positive-trial-results-for-rtu-glucagon-in-hypoglycemia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471701\" data-ts=\"1560775813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471701-lufthansaminus-11-after-profit-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lufthansa -11% after profit warning</a></h4><ul> <li>Shares of Lufthansa (<a href='https://seekingalpha.com/symbol/DLAKF' title='Deutsche Lufthansa AG'>OTCQX:DLAKF</a>, <a href='https://seekingalpha.com/symbol/DLAKY' title='Deutsche Lufthansa AG'>OTCQX:DLAKY</a>) dip after the company <a href=\"https://www.marketwatch.com/story/lufthansa-shares-hit-by-another-profit-warning-2019-06-17?mod=newsviewer_click_realtime\" target=\"_blank\">warns</a> 2019 EBIT margin will be 5.5% and 6.5% vs. a prior forecast of +6.5% to +8.0% as the European market remains challenging.</li>  <li>\"Yields in the European short-haul market, in particular in the group's home markets Germany and Austria, are affected by sustained overcapacities caused by carriers willing to accept significant losses to expand their market share,\" stated Lufthansa.</li> <li>Lufthansa is <font color=\"red\">down 10.99%</font> in Frankfurt trading.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3471701\" data-linked=\"Lufthansa -11% after profit warning\" data-tweet=\"$DLAKF $DLAKY - Lufthansa -11% after profit warning https://seekingalpha.com/news/3471701-lufthansaminus-11-after-profit-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3471701-lufthansaminus-11-after-profit-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471698\" data-ts=\"1560774881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPE\" target=\"_blank\">AMPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471698-ampio-down-31-premarket-on-pricing-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ampio down 31% premarket on pricing stock offering</a></h4><ul> <li>Ampio Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a>) has <a href=\"https://seekingalpha.com/pr/17546011-ampio-pharmaceuticals-announces-pricing-public-offering\" target=\"_blank\">entered</a> into purchase agreements for the purchase of 25,320,000 common shares at $0.40 per share, for gross proceeds of $10.1M.</li><li>The Company anticipates an additional 4,680,000 shares will be sold at the same price at the close of the offering.</li>                  <li>Net proceeds will be used for AP-013 clinical trial and other general corporate purposes.</li><li>The closing date is June 19.</li><li>Shares are down <font color=\"red\">31%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3471558-ampio-slides-22-percent-proposing-stock-offering\" target=\"_blank\">Ampio slides 22% after proposing stock offering</a> (June 14)</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3471698\" data-linked=\"Ampio down 31% premarket on pricing stock offering\" data-tweet=\"$AMPE - Ampio down 31% premarket on pricing stock offering https://seekingalpha.com/news/3471698-ampio-down-31-premarket-on-pricing-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3471698-ampio-down-31-premarket-on-pricing-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471690\" data-ts=\"1560774452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTVA\" target=\"_blank\">CTVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471690-cortevaplus-3-after-deutsche-bank-joins-bull-camp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corteva +3% after Deutsche Bank joins bull camp</a></h4><ul> <li>Shares of Corteva (<a href='https://seekingalpha.com/symbol/CTVA' title='Corteva, Inc.'>CTVA</a> <font color='green'>+0.9%</font>) rally in early trading after Deutsche Bank upgrades the new stock to a Buy rating from Hold.</li> <li>The DB analyst team sees Corteva \"well positioned\" to benefit from higher corn prices and the expected increase in U.S. corn acres in 2020.</li> <li>Deutsche Bank assigns a price target of $32 on Corteva to rep 27% upside potential from last Friday's close. The sell-side analyst community has a consensus <a href=\"https://seekingalpha.com/symbol/CTVA/ratings/sell-side-ratings\" target=\"_blank\">Outperform rating</a> on Corteva.</li> <li>Shares of Corteva are <font color=\"green\">up 3.18%</font> premarket to $26.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471690\" data-linked=\"Corteva +3% after Deutsche Bank joins bull camp\" data-tweet=\"$CTVA - Corteva +3% after Deutsche Bank joins bull camp https://seekingalpha.com/news/3471690-cortevaplus-3-after-deutsche-bank-joins-bull-camp?source=tweet\" data-url=\"https://seekingalpha.com/news/3471690-cortevaplus-3-after-deutsche-bank-joins-bull-camp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471688\" data-ts=\"1560774370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORGS\" target=\"_blank\">ORGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471688-fda-grants-orphan-drug-designation-to-orgenesis-insulin-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants orphan drug designation to Orgenesis&#39; insulin therapy</a></h4><ul><li>Orgenesis (NASDAQ:<a href='https://seekingalpha.com/symbol/ORGS' title='Orgenesis Inc.'>ORGS</a>) <font color=\"green\">+6.7%</font> pre-market on news that the Food and Drug Administration <a href=\"https://seekingalpha.com/pr/17545816-orgenesis-granted-fda-orphan-drug-designation-autologous-insulin-producing-cells-treatment\" target=\"_blank\">granted Orphan Drug designation</a> for its Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy due to chronic pancreatitis.</li><li>The technology is exclusively licensed by the company's wholly-owned Israeli subsidiary from Tel Hashomer Medical Research Infrastructure and Services and is based on the work the company's Chief Scientific Officer, who also is a researcher at THM.</li><li>ORGS says its patented transdifferentiation (or cell reprogramming) process involves  the conversion of one adult tissue or cell into another type of cell, with its distinct phenotype and function; the company's therapy utilizes its transdifferentiation process and its Point of Care liver expansion technology to transform liver cells into AIP cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471688\" data-linked=\"FDA grants orphan drug designation to Orgenesis&#39; insulin therapy\" data-tweet=\"$ORGS - FDA grants orphan drug designation to Orgenesis&#39; insulin therapy https://seekingalpha.com/news/3471688-fda-grants-orphan-drug-designation-to-orgenesis-insulin-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3471688-fda-grants-orphan-drug-designation-to-orgenesis-insulin-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471677\" data-ts=\"1560773079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471677-vbis-hepatitis-b-vaccine-meets-primary-goals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBI&#39;s hepatitis B vaccine meets primary goals</a></h4><ul><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"red\">-21.1%</font> pre-market after announcing a Phase 3 study testing its Sci-B-Vac hepatitis B vaccine against GlaxoSmithKline's (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a>) Engerix-B vaccine <a href=\"https://seekingalpha.com/pr/17545699-vbi-vaccines-announces-positive-top-line-results-protect-pivotal-phase-3-study-sci-b-vac\" target=\"_blank\">met its primary endpoints</a>.</li><li>The trial was designed to evaluate the efficacy and safety of VBI's Sci-B-Vac at a 10 microgram dose against a 20 microgram dose of Engerix-B.</li><li>However, VBI says the study did not meet a secondary objective of non-inferiority of two doses of Sci-B-Vac vs. three doses of Engerix-B.</li><li>VBIV says it remains on track to submit applications for regulatory approvals in the U.S., Europe and Canada beginning mid-year 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3471677\" data-linked=\"VBI&#39;s hepatitis B vaccine meets primary goals\" data-tweet=\"$VBIV $GSK - VBI&#39;s hepatitis B vaccine meets primary goals https://seekingalpha.com/news/3471677-vbis-hepatitis-b-vaccine-meets-primary-goals?source=tweet\" data-url=\"https://seekingalpha.com/news/3471677-vbis-hepatitis-b-vaccine-meets-primary-goals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471676\" data-ts=\"1560773052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZZA\" target=\"_blank\">PZZA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471676-papa-johns-changes-auditor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Papa John&#39;s changes auditor</a></h4><ul> <li>Papa John's International (NASDAQ:<a href='https://seekingalpha.com/symbol/PZZA' title='Papa John&#39;s International, Inc.'>PZZA</a>) says it dismissed KPMG as its financial auditor and appointed Ernst &amp; Young to handle auditing for the current fiscal year.</li> <li>Ernst &amp; Young handled Papa John's books from 1990 to 2017.</li> <li><a href=\"https://seekingalpha.com/filing/4533197\" target=\"_blank\">SEC Form 8-K</a></li> <li>Shares of Papa John's are <font color=\"green\">up 1.58%</font> in premarket trading to $51.54.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471676\" data-linked=\"Papa John&#39;s changes auditor\" data-tweet=\"$PZZA - Papa John&#39;s changes auditor https://seekingalpha.com/news/3471676-papa-johns-changes-auditor?source=tweet\" data-url=\"https://seekingalpha.com/news/3471676-papa-johns-changes-auditor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3471660\" data-ts=\"1560771437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3471660-biotechs-on-watch-after-pfizer-array-blockbuster\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs on watch after Pfizer-Array blockbuster</a></h4><ul> <li>Biotech targets that could see some interest today per Bloomberg after Pfizer ponied up a 62% premium for Array Bio Pharma include Biohaven (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>), Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>), Arena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>), Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a>), Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>), Neurocrine Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a>), BioMarin (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>), Bluebird Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) and Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines Corporation'>BPMC</a>).</li>  <li>The names in the group with premarket bids already in are showing about a <font color=\"green\">1% gain</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3471637-pfizer-acquire-array-biopharma\" target=\"_blank\">Pfizer to acquire Array Biopharma</a> (June 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3471660\" data-linked=\"Biotechs on watch after Pfizer-Array blockbuster\" data-tweet=\"$BHVN $SGEN $ARNA - Biotechs on watch after Pfizer-Array blockbuster https://seekingalpha.com/news/3471660-biotechs-on-watch-after-pfizer-array-blockbuster?source=tweet\" data-url=\"https://seekingalpha.com/news/3471660-biotechs-on-watch-after-pfizer-array-blockbuster\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}